Project Abstract

Cancer is a leading cause of mortality worldwide, and the development of drug resistance remains a significant challenge in the treatment of this devastating disease. Understanding the molecular mechanisms underlying drug resistance in cancer cells is crucial for the development of more effective therapeutic strategies. This project aims to investigate the complex interplay of genetic, epigenetic, and signaling pathways that contribute to the evolution of drug resistance in various cancer cell lines. The project will employ a multifaceted approach to unravel the molecular mechanisms driving drug resistance. First, we will conduct a comprehensive analysis of gene expression profiles in drug-sensitive and drug-resistant cancer cell lines using high-throughput techniques, such as RNA sequencing and microarray analysis. By identifying differentially expressed genes, we will gain insights into the key molecular pathways and signaling networks that are dysregulated in drug-resistant cells. Next, we will explore the role of epigenetic modifications, including DNA methylation and histone modifications, in the development of drug resistance. Epigenetic alterations can lead to the silencing or activation of genes involved in drug response, drug metabolism, and cell survival pathways. We will utilize cutting-edge epigenomic profiling techniques, such as ChIP-seq and bisulfite sequencing, to map the epigenomic landscape of drug-resistant cancer cells and identify key epigenetic regulators of drug resistance. Furthermore, the project will investigate the contribution of cellular signaling pathways to the acquisition of drug resistance. Cancer cells often hijack various signaling cascades, such as the PI3K/Akt, MAPK, and Wnt pathways, to promote cell survival, proliferation, and drug efflux. We will employ pharmacological inhibitors, genetic manipulations, and advanced imaging techniques to dissect the specific signaling mechanisms that confer drug resistance in different cancer cell types. Importantly, this project will also explore the potential of combination therapies and novel drug targeting strategies to overcome drug resistance. By combining our understanding of the molecular mechanisms driving drug resistance with the development of targeted therapeutic approaches, we aim to identify effective treatment strategies that can circumvent or reverse drug resistance in cancer cells. The findings from this project will have significant implications for the clinical management of cancer. By elucidating the complex molecular underpinnings of drug resistance, we can facilitate the development of more personalized and effective cancer treatment regimens. Furthermore, the insights gained from this study may lead to the identification of novel biomarkers and therapeutic targets that can guide the design of next-generation anticancer drugs and improve patient outcomes. In conclusion, this project represents a crucial step in unraveling the molecular mysteries of drug resistance in cancer cells. By integrating cutting-edge technologies and multidisciplinary expertise, we will advance our understanding of the fundamental mechanisms underlying this critical challenge in cancer treatment, paving the way for the development of more effective and personalized therapeutic strategies.

Project Overview